Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics.
Fiche publication
Date publication
novembre 2021
Journal
Expert opinion on investigational drugs
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Barrera-Chimal J, Kolkhof P, Lima-Posada I, Joachim A, Rossignol P, Jaisser F
Lien Pubmed
Résumé
Mineralocorticoid receptor (MR) antagonists (MRAs) provide cardiorenal protection. However steroidal MRAs might induce hyperkalemia and sex hormone-related adverse effects. Several novel non-steroidal MRAs are being developed that are highly selective for the MR and may have an improved safety profile.
Mots clés
AZD9977, KBP-5074, cardiorenal disease, chronic kidney disease, esaxerenone, finerenone, heart failure, hypertension, non-steroidal mineralocorticoid receptor antagonists
Référence
Expert Opin Investig Drugs. 2021 Nov 11;: